Belimumab Decreases Autophagy and Citrullination in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus

Belimumab (BLM) is a B lymphocyte stimulator (BLyS) inhibitor approved for the treatment of systemic lupus erythematosus (SLE). Autophagy is a cell survival mechanism involved in the pathogenesis of SLE. Citrullination is a post-translational modification catalyzed by peptidylarginine deiminase (PAD...

Descripción completa

Detalles Bibliográficos
Autores principales: Colasanti, Tania, Spinelli, Francesca Romana, Barbati, Cristiana, Ceccarelli, Fulvia, Scarpa, Susanna, Vomero, Marta, Alessandri, Cristiano, Valesini, Guido, Conti, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773843/
https://www.ncbi.nlm.nih.gov/pubmed/35053379
http://dx.doi.org/10.3390/cells11020262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773843/
https://www.ncbi.nlm.nih.gov/pubmed/35053379
http://dx.doi.org/10.3390/cells11020262

Ejemplares similares